Figure S2 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer
Mariaelena Pierobon(George Mason University), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Mohammad Jahanzeb(Florida Atlantic University), Julia Wulfkuhle(University of California, San Francisco), Linda Vocila(Translational Genomics Research Institute), Stephen P. Anthony, Massimo Cristofanilli(Cornell University), Nicholas N Hoke(Theranostics (New Zealand)), Donald W. Northfelt(Mayo Clinic in Arizona), Rosa I. Gallagher(George Mason University), Brian Leyland‐Jones(Avera Health), Joyce O’Shaughnessy(Baylor University Medical Center), David W. Craig(City of Hope), Nicholas J. Robert(Tufts Medical Center), Guido Gambara(George Mason University), John D. Carpten(City of Hope), Lance A. Liotta(George Mason University), Jessica Aldrich(Translational Genomics Research Institute), Ting Dong(China Three Gorges University), Shukmei Wong(Translational Genomics Research Institute), Corinne Ramos, Bryant Dunetz(Side-Out Foundation), K. Alex Hodge(George Mason University), Sara A. Byron(Translational Genomics Research Institute)
Cited by 0
Related Papers
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
|The Lancet|2011|1.1k
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|960